Fitch revises AstraZeneca view to stable

Fitch Ratings said it revised AstraZeneca plc's outlook to stable from positive and affirmed the issuer and senior unsecured debt ratings at BBB+.

“The revision of the outlook follows AZ's announcement that it is acquiring U.S. specialist pharma company Alexion for $13.5 billion in cash plus shares representing 15% of AZ's market capitalization worth $25.9 billion (based on reference average ADR price of $54.14),” Fitch said in a press release.

The outlook also considers the added debt AstraZeneca will take on as part of the deal, the agency said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.